ALTHealthcare · BiotechnologyThe 10 Wall Street analysts covering Altimmune, Inc. hold a median 12-month price target of $18 — +452.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Altimmune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (76): Sales and profits are climbing, and climbing faster than before.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +452.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 June 2026 | Leerink Partners | Initiates | Outperform | $10 |
| 18 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 May 2026 | Citizens | Maintains | Market Outperform | — |
| 16 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 7 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2025 | UBS | Maintains | Buy | — |
| 10 July 2025 | JMP Securities | Maintains | Market Outperform | — |
| 27 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 14 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | William Blair | Initiates | Market Perform | — |
| 5 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 21 Sept 2026, Altimmune, Inc. returned −13.8% against +15.7% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 1% of US stocks
Cheaper than 61% of US stocks
Cheaper than 76% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 27% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Altimmune, Inc. has a market value of $632.2M and an enterprise value of $341.9M.
Revenue in the twelve months to 30 June 2026: $31K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$91.8M, a −296000.0% net margin.
Diluted earnings per share, trailing twelve months: $−0.78.
Free cash flow in the twelve months to 30 June 2026: −$76.6M.
Trailing P/E: −3.3×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Altimmune, Inc. employs 57 people — $543.9 of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Altimmune, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Altimmune reported earnings 30 days ago, and its stock has risen 14.2% since that report. The article examines what may be next for the company's shares following that earnings release.
Why it matters — ALT watchers would care because the stock has gained significantly since the earnings report, raising questions about the outlook following that performance.
Altimmune announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. The company is a late clinical-stage biopharmaceutical firm developing pemvidutide for serious liver diseases.
Why it matters — The conference appearance gives Altimmune management a platform to discuss the company's clinical-stage pipeline with investors and healthcare industry attendees.
Altimmune has advanced its drug pemvidutide into Phase III testing for metabolic dysfunction-associated steatohepatitis (MASH), supported by encouraging mid-stage data and regulatory backing, with a data readout expected in 2029.
Why it matters — The Phase III study represents a key clinical milestone for Altimmune's lead candidate, and the 2029 readout gives investors a clear timeline for a potentially significant catalyst.
Zacks reports that Altimmune's stronger cash position supports its pemvidutide programs for MASH, AUD, and ALD, while noting that long timelines, funding needs, and competition remain risks.
Why it matters — An ALT watcher would care because the company's cash position underpins its pipeline progress, while execution risks around timelines, funding, and competition could affect the outlook for pemvidutide.
Altimmune reported a narrower-than-expected Q2 loss. Its $519M in cash is expected to support operations into 2029, while its drug candidate pemvidutide advances across liver and AUD (alcohol use disorder) studies.
Why it matters — A narrower Q2 loss, extended cash runway, and progress in pemvidutide studies are key developments for Altimmune watchers tracking the company's financial health and pipeline.
The 10 Wall Street analysts covering Altimmune, Inc. have a median 12-month price target of $18, with estimates ranging from $11 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Altimmune, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Altimmune, Inc. 26 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Altimmune, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (76 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +452.1% from the last close, and Ticker Nerd's factor model ranks Altimmune, Inc. 26 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Altimmune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $28 over the next 12 months.
Altimmune, Inc. returned -13.8% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases.
The most recent item we track (Zacks Investment Research, 11 Sept 2026): "Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?". Altimmune reported earnings 30 days ago, and its stock has risen 14.2% since that report. The article examines what may be next for the company's shares following that earnings release.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases. The company’s lead product candidate, pemvidutide, is a dual GLP-1 and glucagon receptor agonist being studied for conditions such as metabolic dysfunction-associated steatohepatitis, alcohol use disorder, alcohol-associated liver disease, and obesity. Altimmune is also developing HepTcell, an immunotherapeutic program designed for chronic hepatitis B. Through these programs, Altimmune operates at the intersection of metabolic medicine, hepatology, and immunotherapy, with a pipeline aimed at addressing complex diseases that currently have limited treatment options. The company is headquartered in Gaithersburg, Maryland.
CEO Mr. Jerome Benedict Durso · 57 employees · United States · https://altimmune.com
